Carlson Capital’s Cytokinetics CYTK Stock Holding History

Carlson Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$593K	Buy	9,000 +3,400	+61%	+$216K	0.19%	60
2025 Q4	$356K	Buy	5,600 +900	+19%	+$56K	0.13%	65
2025 Q3	$258K	Sell	4,700 -15,800	-77%	-$651K	0.1%	57
2025 Q2	$677K	Buy	20,500 +13,000	+173%	+$452K	0.28%	36
2025 Q1	$301K	Buy	+7,500	New	+$345K	0.12%	38
2024 Q3	–	Sell	-38,200	Closed	-$2.07M	–	28
2024 Q2	$2.07M	Buy	38,200 +13,200	+53%	+$797K	0.32%	74
2024 Q1	$1.75M	Buy	+25,000	New	+$1.93M	0.14%	94

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Carlson Capital's CYTK Position: Q1 2026 in Review

Carlson Capital increased its Cytokinetics (CYTK) stake by 61% in Q1 2026, buying an estimated $216K and bringing the position to 9,000 shares worth $593K. The position accounts for 0.19% of the portfolio, ranked #60.

Carlson Capital first reported a position in CYTK in Q1 2024 and has held it in 7 quarters since. The position peaked at $2.07M in Q2 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Carlson Capital held 9,000 shares of Cytokinetics worth $593K as of Q1 2026.
Carlson Capital bought 3,400 Cytokinetics shares in Q1 2026, an estimated $216K.
Cytokinetics made up 0.19% of Carlson Capital's portfolio in Q1 2026, its #60 holding.
Carlson Capital first reported a position in Cytokinetics in Q1 2024 and has held it in 7 quarters since.
Carlson Capital's Cytokinetics position peaked at $2.07M in Q2 2024.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Carlson Capital's 13F filing for Q1 2026, filed 28 May 2026.